Autore/Fonte: Josep Carreras Leukaemia Research Institute
Nuova opzione di trattamento per la sclerosi multipla
Read More →
Ottobre 2024
Questo è quello che abbiamo trovato per te
Autore/Fonte: Josep Carreras Leukaemia Research Institute
Accuratezza pari o maggiore dei calcolatori in uso
Approvazione dall’Aifa. Passi avanti anche contro la Bpdcn, una neoplasia molto rara
A due mesi dal varo del piano con cui il Governo punta ad abbatterle mancano all’appello tutti i decreti attuativi attesi
Iacob: “Servono anche misure di prevenzione”
Nei prossimi giorni disponibili servizi prenotazione on-line
Visita all’Istituto di oncologia molecolare di Fondazione Airc
New England Journal of Medicine, Volume 391, Issue 12, Page 1119-1129, September 26, 2024.
La società svilupperà molecole utilizzando un nuovo approccio terapeutico per la cura di tumori intrattabili e patologie genetiche
La società svilupperà molecole utilizzando un nuovo approccio terapeutico per la cura di tumori intrattabili e patologie genetiche
La società svilupperà molecole utilizzando un nuovo approccio terapeutico per la cura di tumori intrattabili e patologie genetiche
La società svilupperà molecole utilizzando un nuovo approccio terapeutico per la cura di tumori intrattabili e patologie genetiche
Introduction
The goal of our research programme is to develop culturally appropriate patient-specific interventions for primary and secondary prevention of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) among people living with HIV (PLWH); PLWH are at a higher risk for OPC than the general population and, as with many cancers, there are disparities in OPC health outcomes by race and ethnicity. Our study incorporates an anti-racist research framework that proposes considering racism as a foundational sociocultural system that causes ill health. We expand the framework to include biases due to gender, sexual orientation, HIV status and membership in other non-dominant groups. Our research programme focuses on HPV-related OPC among people living with PLWH, and on how intersecting identities may impact an individual’s experience with oral health, obtaining regular and appropriate oral healthcare, knowledge and perceptions of oral HPV infection, risk factors for OPC and HPV vaccination.
Methods and analysis
We will follow a grounded theory (GT) qualitative research methodology using focus group discussions (FGDs) to collect data. We will invite PLWH with intersecting identities to participate in one of 12–18 FGDs with 5–8 participants per group. Focus groups will be formed based on self-reported domains, including race, ethnicity, gender identity, sexual orientation and other identities that could impact oral health, such as smoking status, experience with homelessness or experience with drug use disorders. We do not know which aspects of intersecting identities are most salient to accessing oral healthcare. Using FGDs will allow us to gain this knowledge in a setting where participants can build on and reinforce shared understandings about oral healthcare. Following our GT methodology, analysis will occur concurrently with data collection, and emerging concepts or theories may result in changes to focus group guide questions. Initial focus group questions will be organised around our main objectives: (1) to identify individual, interpersonal and structural health equity factors that serve as barriers or facilitators to oral health status and care; (2) to explore knowledge and perceptions about causes, risk factors, prevention and screening for oral or OPC and (3) to elicit recommendations for improving access to regular and appropriate oral healthcare and suggestions on engaging PLWH from diverse identity groups in prevention interventions.
Ethics and dissemination
All methods and procedures were approved by the University of California, San Francisco, Institutional Review Board (approval number: 23-39307) and are in accordance with the Declaration of Helsinki of 1975, as revised in 2000. Participants are required to provide informed consent. The results of this study will be presented at scholarly meetings and published in peer-reviewed journals. In addition, a lay summary of results will be created and distributed to our participants and community through our website and social media.
Trial registration number
NCT06055868.
In aumento, un terzo dei pazienti riceve diagnosi dopo 5 anni
In aumento, un terzo dei pazienti riceve diagnosi dopo 5 anni
Colpiti in 500mila, il farmaco è per forme moderate e severe